Bioavailability of Celecoxib Formulated with Mesoporous Magnesium Carbonate—An In Vivo Evaluation
An attractive approach to increase the aqueous apparent solubility of poorly soluble drugs is to formulate them in their amorphous state. In the present study, celecoxib, a poorly soluble drug, was successfully loaded into mesoporous magnesium carbonate (MMC) in its amorphous state via a solvent eva...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-09-01
|
| Series: | Molecules |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1420-3049/27/19/6188 |
| _version_ | 1827653963072143360 |
|---|---|
| author | Teresa Zardán Gómez de la Torre Tuulikki Lindmark Ocean Cheung Christel Bergström Maria Strømme |
| author_facet | Teresa Zardán Gómez de la Torre Tuulikki Lindmark Ocean Cheung Christel Bergström Maria Strømme |
| author_sort | Teresa Zardán Gómez de la Torre |
| collection | DOAJ |
| description | An attractive approach to increase the aqueous apparent solubility of poorly soluble drugs is to formulate them in their amorphous state. In the present study, celecoxib, a poorly soluble drug, was successfully loaded into mesoporous magnesium carbonate (MMC) in its amorphous state via a solvent evaporation method. Crystallization of celecoxib was suppressed, and no reaction with the carrier was detected. The MMC formulation was evaluated in vitro and in vivo in terms of oral bioavailability. Celebra<sup>®</sup>, a commercially available formulation, was used as a reference. The two celecoxib formulations were orally administrated in male rats (average of <i>n</i> = 6 animals per group), and blood samples for plasma were taken from all animals at different time points after administration. There was no statistical difference (<i>p</i> > 0.05) in AUC<sub>inf</sub> between the two formulations. The results showed that MMC may be a promising drug delivery excipient for increasing the bioavailability of compounds with solubility-limited absorption. |
| first_indexed | 2024-03-09T21:26:59Z |
| format | Article |
| id | doaj.art-d4772167cd1e4734b0519c00ecf1a78a |
| institution | Directory Open Access Journal |
| issn | 1420-3049 |
| language | English |
| last_indexed | 2024-03-09T21:26:59Z |
| publishDate | 2022-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Molecules |
| spelling | doaj.art-d4772167cd1e4734b0519c00ecf1a78a2023-11-23T21:07:20ZengMDPI AGMolecules1420-30492022-09-012719618810.3390/molecules27196188Bioavailability of Celecoxib Formulated with Mesoporous Magnesium Carbonate—An In Vivo EvaluationTeresa Zardán Gómez de la Torre0Tuulikki Lindmark1Ocean Cheung2Christel Bergström3Maria Strømme4Department of Materials Science and Engineering, Uppsala University, Box 35, 751 03 Uppsala, SwedenDisruptive Pharma AB, Dag Hammarskjölds Väg 54B, 751 83 Uppsala, SwedenDepartment of Materials Science and Engineering, Uppsala University, Box 35, 751 03 Uppsala, SwedenDepartment of Pharmacy, Drug Delivery, Uppsala University, Box 580, 751 23 Uppsala, SwedenDepartment of Materials Science and Engineering, Uppsala University, Box 35, 751 03 Uppsala, SwedenAn attractive approach to increase the aqueous apparent solubility of poorly soluble drugs is to formulate them in their amorphous state. In the present study, celecoxib, a poorly soluble drug, was successfully loaded into mesoporous magnesium carbonate (MMC) in its amorphous state via a solvent evaporation method. Crystallization of celecoxib was suppressed, and no reaction with the carrier was detected. The MMC formulation was evaluated in vitro and in vivo in terms of oral bioavailability. Celebra<sup>®</sup>, a commercially available formulation, was used as a reference. The two celecoxib formulations were orally administrated in male rats (average of <i>n</i> = 6 animals per group), and blood samples for plasma were taken from all animals at different time points after administration. There was no statistical difference (<i>p</i> > 0.05) in AUC<sub>inf</sub> between the two formulations. The results showed that MMC may be a promising drug delivery excipient for increasing the bioavailability of compounds with solubility-limited absorption.https://www.mdpi.com/1420-3049/27/19/6188mesoporous materialsmagnesium carbonatepoorly soluble drugcelecoxibdrug releasebioavailability |
| spellingShingle | Teresa Zardán Gómez de la Torre Tuulikki Lindmark Ocean Cheung Christel Bergström Maria Strømme Bioavailability of Celecoxib Formulated with Mesoporous Magnesium Carbonate—An In Vivo Evaluation Molecules mesoporous materials magnesium carbonate poorly soluble drug celecoxib drug release bioavailability |
| title | Bioavailability of Celecoxib Formulated with Mesoporous Magnesium Carbonate—An In Vivo Evaluation |
| title_full | Bioavailability of Celecoxib Formulated with Mesoporous Magnesium Carbonate—An In Vivo Evaluation |
| title_fullStr | Bioavailability of Celecoxib Formulated with Mesoporous Magnesium Carbonate—An In Vivo Evaluation |
| title_full_unstemmed | Bioavailability of Celecoxib Formulated with Mesoporous Magnesium Carbonate—An In Vivo Evaluation |
| title_short | Bioavailability of Celecoxib Formulated with Mesoporous Magnesium Carbonate—An In Vivo Evaluation |
| title_sort | bioavailability of celecoxib formulated with mesoporous magnesium carbonate an in vivo evaluation |
| topic | mesoporous materials magnesium carbonate poorly soluble drug celecoxib drug release bioavailability |
| url | https://www.mdpi.com/1420-3049/27/19/6188 |
| work_keys_str_mv | AT teresazardangomezdelatorre bioavailabilityofcelecoxibformulatedwithmesoporousmagnesiumcarbonateaninvivoevaluation AT tuulikkilindmark bioavailabilityofcelecoxibformulatedwithmesoporousmagnesiumcarbonateaninvivoevaluation AT oceancheung bioavailabilityofcelecoxibformulatedwithmesoporousmagnesiumcarbonateaninvivoevaluation AT christelbergstrom bioavailabilityofcelecoxibformulatedwithmesoporousmagnesiumcarbonateaninvivoevaluation AT mariastrømme bioavailabilityofcelecoxibformulatedwithmesoporousmagnesiumcarbonateaninvivoevaluation |